What Analysts Are Saying About Axsome Therapeutics Stock
Portfolio Pulse from Benzinga Insights
Axsome Therapeutics (NASDAQ:AXSM) has received mixed analyst ratings, with a recent upward trend in 12-month price targets, now averaging $123.46. The company, a clinical-stage biopharmaceutical focused on CNS disorders, has shown significant revenue growth of 193.5% as of December 31, 2023, but struggles with profitability and debt management. Analysts' actions and price target adjustments reflect their reactions to market conditions and company performance.
March 19, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics has seen a positive shift in analyst sentiment with an upward trend in price targets, indicating bullish prospects. However, concerns about profitability and high debt may temper investor enthusiasm.
The increase in the average price target to $123.46 reflects a positive outlook from analysts, suggesting potential stock appreciation. However, the company's financial challenges, such as a net margin of -137.92% and a high debt-to-equity ratio of 0.98, may pose risks to achieving these targets. The mixed analyst ratings, with recent adjustments, indicate a cautiously optimistic view on the stock's short-term performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100